What the Evidence Says: Cannabis by Condition
One of the most common questions we hear at Cura Vida Cannabis Clinics is simple: will this actually help my condition?
It deserves a straight answer. Medical cannabis is not a universal remedy, and the strength of the evidence varies enormously depending on what you are treating. For a few conditions the research is solid. For many it is promising but preliminary. For at least one, the evidence says cannabis does not help at all.
This article summarises where things currently stand. We have tried to be honest rather than optimistic, because a treatment decision built on overstated claims is not a good treatment decision.
How to read the evidence
Before the condition list, three points worth understanding.
Cannabis is not one drug. THC, CBD, and more than a hundred other cannabinoids behave differently, and a study of purified CBD tells you little about inhaled high-THC flower. When you read that "cannabis helps X," always ask which cannabinoid, at what dose, by what route.
Regulatory approval and clinical evidence are different things. Several isolated cannabinoid medicines have been approved by regulators internationally for specific indications. The whole plant has not been approved as a medicine in most jurisdictions, which reflects the difficulty of standardising a botanical product as much as it reflects the evidence.
Absence of strong evidence is not proof of no effect. Cannabis research has been legally constrained for decades. Many conditions sit in a category best described as "plausible, reported by patients, not yet well studied."
Where the evidence is strongest
Nausea and vomiting from chemotherapy. This is among the best-established uses. Cannabinoid medicines have a long track record here and are an established option when standard antiemetics are insufficient.
Rare, severe childhood epilepsy syndromes. Purified pharmaceutical-grade CBD has demonstrated seizure reduction in specific syndromes in controlled trials. This is a narrow indication involving specialist care, not general epilepsy management.
Appetite and weight loss in HIV/AIDS. Cannabinoid medicines have an established role in stimulating appetite in this population.
Where the evidence is moderate
Chronic pain, especially neuropathic pain. This is the single most common reason patients come to us. Systematic reviews generally find modest but real benefit, with THC-containing formulations carrying more of the analgesic effect than CBD alone. "Modest" is the operative word: most patients experience meaningful improvement in pain and function rather than elimination of pain. Set expectations accordingly.
Multiple sclerosis symptoms. Reasonable evidence supports benefit for spasticity and associated pain, particularly with balanced THC/CBD formulations.
Reducing opioid doses. Some patients are able to lower their opioid requirement with cannabis added to their regimen. The population-level research is genuinely mixed and this should never be attempted without physician supervision, but for individual patients under careful management it can be a worthwhile goal.
Where the evidence is early or mixed
Sleep problems. Enormously common as a reason for use, and many patients report benefit. The controlled research is less encouraging than patient reports, and there are open questions about tolerance developing over time and about effects on sleep architecture. Cannabis may be a reasonable option for sleep, but it should not be the first thing tried, and cognitive behavioural therapy for insomnia remains the better-supported approach.
Anxiety. CBD shows some promise in early research. THC is more complicated, as it can reduce anxiety at lower doses and provoke it at higher ones. Dose matters more here than almost anywhere else.
PTSD. Widely used by patients, weakly supported by controlled trials so far. Reviews to date have generally not found strong evidence of benefit.
Inflammatory bowel disease and irritable bowel syndrome. Some patients report symptom relief, particularly for pain and appetite, but evidence that cannabis alters the underlying disease process in IBD is lacking.
Tourette syndrome and other movement disorders. Early and limited.
Where the evidence says no
Glaucoma. Cannabis does briefly lower intraocular pressure, but the effect is too short-lived to be clinically useful, and treating glaucoma with cannabis instead of proven therapy risks vision loss. This is not a condition we treat with cannabis.
What this means for your consultation
Evidence strength is one input into a treatment decision, not the whole decision. Your CVCC physician will also weigh what you have already tried, your other medications and conditions, your goals, and your tolerance for side effects.
Two principles guide how we use this evidence:
We will tell you when the evidence for your condition is thin. Trying cannabis for a condition with limited research is sometimes reasonable, particularly when conventional options have failed, but you should make that choice knowing it is what you are doing.
We will not encourage you to substitute cannabis for a treatment that is known to work. Cannabis is frequently a useful addition to a treatment plan. It is far less often a replacement for one.
Talk to us
If you would like to discuss what medical cannabis might realistically offer for your specific condition, schedule a telehealth consultation with a CVCC physician.
This article is for general education and does not constitute individual medical advice. Evidence evolves; this summary reflects our understanding at the time of writing. Always consult a qualified physician before starting, changing, or stopping any treatment.
Primary source: NCCIH (US National Institutes of Health), "Cannabis (Marijuana) and Cannabinoids: What You Need To Know." Note for our editorial team: the NCCIH fact sheet is public domain, but its last major update was 2019, and several condition sections should be checked against more recent systematic reviews before this article is finalised.